title: [Comparative susceptibility evolution in Escherichia coli from urinary tract infections in outpatients and inpatients at Perpignan hospital in 2002 and 2004].
abstract: The medical emergency ward makes a link between outpatients and hospitalized ones, so we can study community bacterial ecology. The antibiotic susceptibility in Escherichia coli strains isolated from urinary tract infections (UTI) of patients consulting at emergency ward of our hospital in 2002 and 2004 was determined and compared with the susceptibility of the same strains isolated from UTI of hospitalized patients on the same period. The antibiotic susceptibility was performed with Microscan (Dade Behring). All bacteria were tested against the following antimicrobial agents: amoxicilline (Amx), l'amoxicilline+clavulanic acid (AMC), nalidixic acid (NA), ciprofloxacine (Cip), cotrimoxazole (SXT), nitrofurantoin (Ft). Susceptibility in E. coli strains isolated from outpatients vary from 58 to 54% for Amx, from 88 to 83% for NA, from 96 to 89% for Cip, from 82 to 79% for SXT, from 94 to 96% for Ft and remains at 60% for AMC from 2002 to 2004. Susceptibility in E. coli strains isolated from hospitalized patients vary from 52 to 47% for Amx, 55 to 53% for AMC, from 79 to 70% for NA, from 87 to 79% for Cip, from 74 to 69% for SXT, from 93 to 92% for Ft. Susceptibility in E. coli strains isolated in the community from UTI outpatients is decreasing and it becomes worrying particularly concerning the fluoroquinolones, therefore empiric treatment of pyelonephritis by fluoroquinolones must be assessed again.
authors.affiliation: Service de microbiologie-hématologie, hôpital Saint-Jean, pôle infectiologie de l'hôpital Saint-Jean, avenue du Languedoc, 66000 Perpignan, France.
authors.forename: M-L
authors.initials: ML
authors.lastname: Lemort
authors.forename: S
authors.initials: S
authors.lastname: Neuville
authors.forename: M
authors.initials: M
authors.lastname: Medus
authors.forename: P
authors.initials: P
authors.lastname: Gueudet
authors.forename: M
authors.initials: M
authors.lastname: Saada
authors.forename: H
authors.initials: H
authors.lastname: Aumaître
authors.forename: E
authors.initials: E
authors.lastname: Lecaillon
mesh_terms: D000900:Anti-Bacterial Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use; D004198:Disease Susceptibility; D004636:Emergency Service, Hospital / Q000706:statistics & numerical data; D004926:Escherichia coli / Q000187:drug effects; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000453:epidemiology*; D005602:France / Q000453:epidemiology; D006801:Humans; D007297:Inpatients / Q000706:statistics & numerical data*; D008826:Microbial Sensitivity Tests; D010045:Outpatients / Q000706:statistics & numerical data*; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000453:epidemiology*
chemical_list: D000900:Anti-Bacterial Agents